VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
---|---|---|---|---|---|---|---|---|
TVIS10044928 | HBV | ENSG00000173198.6 | protein_coding | CYSLTR1 | No | No | 10800 | Q9Y271 |
TVIS44029725 | HTLV-1 | ENSG00000173198.6 | protein_coding | CYSLTR1 | No | No | 10800 | Q9Y271 |
TVIS44051802 | HTLV-1 | ENSG00000173198.6 | protein_coding | CYSLTR1 | No | No | 10800 | Q9Y271 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
Gene | CYSLTR1 |
---|---|
DrugBank ID | DB01411 |
Drug Name | Pranlukast |
Target ID | BE0000705 |
UniProt ID | Q9Y271 |
Regulation Type | antagonist |
PubMed IDs | 11264758; 11854273; 15475658; 16864492; 17112405; 11752352; 23859232; 18176092; 21482134; 12801316; 15609771; 31390227; 18031150 |
Citations | Yoo SH, Park SH, Song JS, Kang KH, Park CS, Yoo JH, Choi BW, Hahn MH: Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial. Respirology. 2001 Mar;6(1):15-21.@@Ogasawara H, Ishii S, Yokomizo T, Kakinuma T, Komine M, Tamaki K, Shimizu T, Izumi T: Characterization of mouse cysteinyl leukotriene receptors mCysLT1 and mCysLT2: differential pharmacological properties and tissue distribution. J Biol Chem. 2002 May 24;277(21):18763-8. Epub 2002 Feb 19.@@Ishinaga H, Takeuchi K, Kishioka C, Suzuki S, Basbaum C, Majima Y: Pranlukast inhibits NF-kappaB activation and MUC2 gene expression in cultured human epithelial cells. Pharmacology. 2005 Feb;73(2):89-96. Epub 2004 Oct 5.@@Shirasaki H, Kanaizumi E, Seki N, Kikuchi M, Watanabe K, Konno N, Himi T: Distribution of specific binding sites for cysteinyl leukotriene 1 receptor antagonist in human nasal mucosa. Acta Otolaryngol. 2006 Sep;126(9):948-51.@@Ding Q, Wei EQ, Zhang YJ, Zhang WP, Chen Z: Cysteinyl leukotriene receptor 1 is involved in N-methyl-D-aspartate-mediated neuronal injury in mice. Acta Pharmacol Sin. 2006 Dec;27(12):1526-36.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Singh RK, Tandon R, Dastidar SG, Ray A: A review on leukotrienes and their receptors with reference to asthma. J Asthma. 2013 Nov;50(9):922-31. doi: 10.3109/02770903.2013.823447. Epub 2013 Aug 16.@@Suzuki S, Takeuchi K, Ishinaga H, Basbaum C, Majima Y: Leukotriene D4 upregulates MUC2 gene transcription in human epithelial cells. Pharmacology. 2008;81(3):221-8. doi: 10.1159/000112866. Epub 2008 Jan 7.@@Haneda Y, Hasegawa S, Hirano R, Hashimoto K, Ohsaki A, Ichiyama T: Leukotriene D4 enhances tumor necrosis factor-alpha-induced vascular endothelial growth factor production in human monocytes/macrophages. Cytokine. 2011 Jul;55(1):24-8. doi: 10.1016/j.cyto.2011.03.018. Epub 2011 Apr 8.@@Ichiyama T, Hasegawa S, Umeda M, Terai K, Matsubara T, Furukawa S: Pranlukast inhibits NF-kappa B activation in human monocytes/macrophages and T cells. Clin Exp Allergy. 2003 Jun;33(6):802-7.@@Saito K, Nagata M, Kikuchi I, Sakamoto Y: Leukotriene D4 and eosinophil transendothelial migration, superoxide generation, and degranulation via beta2 integrin. Ann Allergy Asthma Immunol. 2004 Dec;93(6):594-600. doi: 10.1016/S1081-1206(10)61269-0.@@Figueroa EE, Kramer M, Strange K, Denton JS: CysLT1 receptor antagonists pranlukast and zafirlukast inhibit LRRC8-mediated volume regulated anion channels independently of the receptor. Am J Physiol Cell Physiol. 2019 Oct 1;317(4):C857-C866. doi: 10.1152/ajpcell.00281.2019. Epub 2019 Aug 7.@@Reques FG, Rodriguez JL: Tolerability of leukotriene modifiers in asthma: a review of clinical experience. BioDrugs. 1999 Jun;11(6):385-94. doi: 10.2165/00063030-199911060-00003. |
Groups | Investigational |
Direct Classification | Chromones |
SMILES | O=C(NC1=C2OC(=CC(=O)C2=CC=C1)C1=NNN=N1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1 |
Pathways | |
PharmGKB | PA134698661 |
ChEMBL | CHEMBL21333 |